Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th
1.7.2021 18:35:00 EEST | Business Wire | Press release
Amazon Prime Video today announced the exclusive global premiere (outside of Japan) of the highly anticipated Japanese anime blockbuster EVANGELION:3.0+1.01 THRICE UPON A TIME on August 13th. EVANGELION:3.0+1.01 THRICE UPON A TIME is the fourth and final chapter of the new theatrical edition of Evangelion. The anime film – which is the highest-grossing in all movies by chief director Hideaki Anno and most-watched movie in Japanese theatres in 2021- is from directors Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda as well as legendary creator, screenwriter and chief director Hideaki Anno (Shin Godzilla). To celebrate the finale of the franchise, Prime Video will also release the three previous movies, EVANGELION:1.11 YOU ARE (NOT) ALONE., EVANGELION:2.22 YOU CAN (NOT) ADVANCE., EVANGELION:3.33 YOU CAN (NOT) REDO. to fans in more than 240 countries and territories.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210701005692/en/
Japanese Record-Breaking Anime Blockbuster Film EVANGELION:3.0+1.01 THRICE UPON A TIME to Launch Exclusively on Amazon Prime Video on August 13th (Graphic: Business Wire)
The blockbuster franchise is a Japanese anime pop culture phenomenon based on the story of Evangelion, an artificial human and multipurpose humanoid weapon, and the Angels, an unknown life-form which takes place after the Earth has been shattered by a cataclysmic event. The film features all original voice actors including Megumi Ogata, Megumi Hayashibara, Yûko Miyamura and uses the latest imaging technology to showcase the personalities and relationships of its unique characters as they fight for survival. It will be dubbed in 10 languages including English, French, German, Portuguese, Spanish and Italian, and offer subtitles in 28 languages.
Since the TV series first aired in 1995, the Evangelion franchise has had a significant impact on Japanese pop culture and has elevated the anime genre worldwide. The legendary anime franchise was then reborn as a new movie series Evangelion: New Theatrical Edition in 2007 and this fourth and final movie released across theatres in Japan in March has gone on to break records, both for Hideaki Anno’s films and also as Japan’s most-watched theatrical movie of the year. EVANGELION:3.0+1.01 THRICE UPON A TIME on Amazon Prime Video will be the latest version of the film which includes revised scenes and is releasing across theatres now in Japan.
“The EVANGELION films have been thrilling fans for years and we know that there is a huge appetite around the world for the finale,” said Brad Beale, Vice President, Worldwide Content Licensing Prime Video. “I’m excited for Prime members worldwide to finally have the opportunity to watch the anime masterpiece EVANGELION:3.0+1.01 THRICE UPON A TIME, as well as the three previous films.”
“I’d like to thank every Eva fan in the world for your continued support,” said Hideaki Anno, Creator, Screenwriter and Chief Director. “We were looking for the best way to offer the movie to fans overseas as early as possible in a challenging situation with movie theatres during COVID-19, and are happy to have found Prime Video as a partner to stream it globally. We highly recommend watching it on a big TV screen for the best viewing experience.”
ABOUT
EVANGELION:3.0+1.01 THRICE UPON A TIME
The fourth and final installment of the Rebuild of Evangelion. Misato and her anti-Nerv group Wille arrive in Paris, a city now red from core-ization. Crew from the flagship Wunder land on a containment tower. They only have 720 seconds to restore the city. When a horde of Nerv Evas appear, Mari’s improved Eva Unit 8 must intercept. Meanwhile, Shinji, Asuka, and Rei (provisional name) wander around Japan.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Kazuya Tsurumaki, Katsuichi Nakayama and Mahiro Maeda, Screenwriter: Hideaki Anno
ABOUT THE THREE PREVIOUS MOVIES
EVANGELION:1.11 YOU ARE (NOT) ALONE.
Scarred by the Second Impact, the Fourth Angel attacks Tokyo III and humanity's fate is left in the hands of Special Government Agency Nerv. Young Shinji Ikari is forced to pilot EVA-01. He and EVA-00 pilot Rei Ayanami are tasked to fight, but EVA-01 is damaged by the Sixth Angel. Misato Katsuragi draws up a plan to focus all of Japan's electricity into EVA-01's positron cannon to defeat the Angel.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:2.22 YOU CAN (NOT) ADVANCE.
Mari Illustrious-Makinami pilots Provisional Unit-05 to defeat the excavated Third Angel. Asuka Langley-Shikinami and EVA-02 defeat the Seventh Angel. The Eighth Angel appears and attacks Nerv HQ. EVA-03 is taken over by the Ninth Angel during testing and Shinji deploys to stop it, but learns Asuka is aboard. Gendo switches EVA-01's controls over to the Dummy System and begins fighting EVA-03.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.33 YOU CAN (NOT) REDO.
Shinji wakes after 14 years aboard the battleship AAA Wunder belonging to an anti-Nerv organization founded by former Nerv members. Shinji hears Rei's voice coming from EVA Mark.09, sent to rescue him, so he leaves Wunder and heads to Nerv. Kaworu Nagisa shows Shinji the transformed land. He learns that saving Rei triggered the Near Third Impact that caused the catastrophic damage to Earth.
Studio: khara, Inc.
Chief director: Hideaki Anno, Director: Masayuki, Mahiro Maeda and Kazuya Tsurumaki, Screenwriter: Hideaki Anno
EVANGELION:3.0+1.01 THRICE UPON A TIME will join the thousands of TV shows and movies in the Prime Video catalogue, including award-winning and critically acclaimed global Amazon Originals like Borat Subsequent Moviefilm, Tom Clancy's Jack Ryan, The Boys, Hunters, Fleabag, and The Marvelous Mrs. Maisel. All this is available on Prime Video at no extra cost for Prime members. Prime members will be able to watch EVANGELION:3.0+1.01 THRICE UPON A TIME anywhere and anytime on the Prime Video app for smart TVs, mobile devices, Fire TV, Fire TV stick, Fire tablets, Apple TV, and stream online. In the Prime Video app, Prime members can download episodes on their mobile devices and tablets and watch anywhere offline.
Amazon
Amazon is guided by four principles: customer obsession rather than competitor focus, passion for invention, commitment to operational excellence, and long-term thinking. Customer reviews, 1-Click shopping, personalized recommendations, Prime, Fulfillment by Amazon, AWS, Kindle Direct Publishing, Kindle, Fire tablets, Fire TV, Amazon Echo, and Alexa are some of the products and services pioneered by Amazon. For more information, visit amazon.com/about and follow @AmazonNews.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210701005692/en/
Contact information
Press Contacts for Prime Video & Amazon Studios:
Arianne Rocchi: roccha@amazon.com
Ayumi Sakaguchi: ayusaka@amazon.co.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom